Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312633765> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4312633765 abstract "<h3>Introduction/Background</h3> Survival benefit of secondary cytoreductive surgery (SCS) in platinum-sensitive relapsed ovarian cancer (PSROC) has been demonstrated in recent randomised controlled trials. Data on SCS for PSROC from resource-limited settings are scarce. This study aimed to evaluate the perioperative and oncologic outcomes of SCS in Indian women with PSROC. <h3>Methodology</h3> A review was conducted for all patients who underwent SCS for PSROC between 2012 and 2021 at Tata Medical Center. Clinical information including patient and disease characteristics, surgical details, and survival data was extracted from electronic medical records. Survival analysis was done using Kaplan-Meier method and Cox Proportional Hazards model. <h3>Results</h3> Fifty patients (age 30–71) underwent SCS for PSROC with complete cytoreduction (CC0) achieved in 35 (70%) patients. The majority had high-grade serous carcinoma (78%), and most patients (88%) relapsed more than 12 months after platinum-based chemotherapy. SCS involved bowel resection in 24% of patients with stoma in 10%. Clavien-Dindo grade 3 or higher complications occurred in 4 (8%) patients. Postoperative 30-day mortality rate was 2%. Maintenance therapy with bevacizumab, and poly ADP ribose polymerase (PARP) inhibitor was used in 28% and 8% of patients respectively. The median progression-free survival (PFS) was 16 months (95% confidence interval [CI], 13.9 to 18.1), and the median overall survival (OS) was 38 months (95% CI, 32.3 to 43.7). Patients with CC0 had a better PFS than those without CC0 (18 months vs. 14 months; hazard ratio, 0.38; 95% CI, 0.18 to 0.8; P=0.01) but not OS. There was no significant difference in PFS and OS among other potential prognostic subgroups. <h3>Conclusion</h3> Secondary cytoreductive surgery in PSROC had minimal complications. Progression-free survival was comparable to randomised studies while overall survival was lower. Patients with complete cytoreduction had better progression-free survival." @default.
- W4312633765 created "2023-01-05" @default.
- W4312633765 creator A5012032416 @default.
- W4312633765 creator A5026749756 @default.
- W4312633765 creator A5044913071 @default.
- W4312633765 creator A5055434739 @default.
- W4312633765 creator A5065099143 @default.
- W4312633765 date "2022-10-01" @default.
- W4312633765 modified "2023-09-25" @default.
- W4312633765 title "2022-RA-1661-ESGO Secondary cytoreductive surgery in platinum-sensitive relapsed ovarian cancer: real-world experience from an indian cancer centre" @default.
- W4312633765 doi "https://doi.org/10.1136/ijgc-2022-esgo.768" @default.
- W4312633765 hasPublicationYear "2022" @default.
- W4312633765 type Work @default.
- W4312633765 citedByCount "0" @default.
- W4312633765 crossrefType "proceedings-article" @default.
- W4312633765 hasAuthorship W4312633765A5012032416 @default.
- W4312633765 hasAuthorship W4312633765A5026749756 @default.
- W4312633765 hasAuthorship W4312633765A5044913071 @default.
- W4312633765 hasAuthorship W4312633765A5055434739 @default.
- W4312633765 hasAuthorship W4312633765A5065099143 @default.
- W4312633765 hasBestOaLocation W43126337651 @default.
- W4312633765 hasConcept C121608353 @default.
- W4312633765 hasConcept C126322002 @default.
- W4312633765 hasConcept C141071460 @default.
- W4312633765 hasConcept C143998085 @default.
- W4312633765 hasConcept C150173356 @default.
- W4312633765 hasConcept C207103383 @default.
- W4312633765 hasConcept C2776694085 @default.
- W4312633765 hasConcept C2777802072 @default.
- W4312633765 hasConcept C2780427987 @default.
- W4312633765 hasConcept C2780739268 @default.
- W4312633765 hasConcept C2780962732 @default.
- W4312633765 hasConcept C31174226 @default.
- W4312633765 hasConcept C44249647 @default.
- W4312633765 hasConcept C526805850 @default.
- W4312633765 hasConcept C71924100 @default.
- W4312633765 hasConceptScore W4312633765C121608353 @default.
- W4312633765 hasConceptScore W4312633765C126322002 @default.
- W4312633765 hasConceptScore W4312633765C141071460 @default.
- W4312633765 hasConceptScore W4312633765C143998085 @default.
- W4312633765 hasConceptScore W4312633765C150173356 @default.
- W4312633765 hasConceptScore W4312633765C207103383 @default.
- W4312633765 hasConceptScore W4312633765C2776694085 @default.
- W4312633765 hasConceptScore W4312633765C2777802072 @default.
- W4312633765 hasConceptScore W4312633765C2780427987 @default.
- W4312633765 hasConceptScore W4312633765C2780739268 @default.
- W4312633765 hasConceptScore W4312633765C2780962732 @default.
- W4312633765 hasConceptScore W4312633765C31174226 @default.
- W4312633765 hasConceptScore W4312633765C44249647 @default.
- W4312633765 hasConceptScore W4312633765C526805850 @default.
- W4312633765 hasConceptScore W4312633765C71924100 @default.
- W4312633765 hasLocation W43126337651 @default.
- W4312633765 hasOpenAccess W4312633765 @default.
- W4312633765 hasPrimaryLocation W43126337651 @default.
- W4312633765 hasRelatedWork W1963973664 @default.
- W4312633765 hasRelatedWork W1997133872 @default.
- W4312633765 hasRelatedWork W2050348440 @default.
- W4312633765 hasRelatedWork W2051540233 @default.
- W4312633765 hasRelatedWork W2098707609 @default.
- W4312633765 hasRelatedWork W2145753255 @default.
- W4312633765 hasRelatedWork W2316610093 @default.
- W4312633765 hasRelatedWork W2340695374 @default.
- W4312633765 hasRelatedWork W2545945608 @default.
- W4312633765 hasRelatedWork W1967062665 @default.
- W4312633765 isParatext "false" @default.
- W4312633765 isRetracted "false" @default.
- W4312633765 workType "article" @default.